Dechra acquires Sucromate™ Equine (deslorelin acetate) sterile suspension from Thorn Bioscience L.L.C

Friday, October 29, 2021

This acquisition expands Dechra’s equine portfolio in the reproductive category.

Dechra is pleased to announce the acquisition of Sucromate™ Equine (deslorelin acetate) sterile suspension from Thorn Bioscience L.L.C. This acquisition expands Dechra’s equine portfolio in the reproductive category.

Mike Eldred, President of Dechra North America, stated, “Sucromate Equine is a sterile, synthetic gonadotropin-releasing hormone (GnRH) analog suspension that veterinarians have used and relied on for their breeding operations. Sucromate Equine expands Dechra’s reproductive portfolio and complements our existing product offering.”

Sucromate Equine (deslorelin acetate) sterile suspension should be used exclusively by veterinarians.

The product is now available for veterinarians to purchase through select veterinary distributors.

About Dechra

Dechra Veterinary Products’ equine portfolio includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, and Osteokine® (PRP). Dechra also offers Equidone® Gel (domperidone), the Vetivex® line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical dermatologic products. The recent additions of ProVet™ APC (Autologous Platelet Concentrate) system, Rompun® (xylazine injection), Butorphanol Tartrate Injection, and Zimeta® (dipyrone injection) further expand Dechra’s equine offerings.

For questions or further information, please contact Mike Eldred or Doug Hubert:

Mike Eldred, President, North American Operations, Dechra Veterinary Products, Mike.Eldred@Dechra.com

Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products, Doug.Hubert@Dechra.com